I agree!; ). Detangling simplifies a big move whatever that move may be that fulfills the statement that NWBO would look like a very different company; ). I can think and have thought of some nice merger and acquisition possibilities and I guarantee that Linda and some others are way ahead of me on this; ). Best wishes.
GoodGuyBill, On your question on why unify the full stack now (acquisition of Advent CDMO, manufacturing, IP, trial data) right before a regulatory decision:
Here are my thoughts, as I believe NWBO wants to build a dominant franchise:
Operational - Prior to major ramp-up in commercialization, ownership is best. - Direct control is crucial for quality assurance and process consistency.
Regulatory - An important "check the box" item for MHRA during labeling and approval negotiations - Assures regulators of NWBO’s commitment and capability to scaling-up production by bringing critical functions in-house.
Financial - Acquisition of Advent means NWBO does not pay a CDMO a 15% mark up. That directly increases NWBO’s gross margin %. - Post-approval, analysts will focus on financial forecasts, specifically Gross margin and Net Profit. - Strong GM % relative to biotech peers is critical for Institutional investor comparisons and assigning valuation premiums before a financing.
Market Data 
Markets 
AI
Hi Sir, I'm just buying as much as I can. I thought big news behind the Scene after LP sold Advent to nwbo. Partnership/Merger/BO? 
